MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma

MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma

Background & Aims: The mechanism underlying resistance to immunotherapy involves engagement of immune checkpoint pathways. The transcriptional and epigenetic processes of checkpoint molecules, however, have not been well investigated. We thus studied whether the transcription factor myeloid...

Full description

Bibliographic Details
Main Authors: Anna Kan, Shuang Liu, Minke He, Dongsheng Wen, Haijing Deng, Lichang Huang, Zhicheng Lai, Yexing Huang, Ming Shi
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:JHEP Reports
Subjects:
tumour microenvironment
immune checkpoint
targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923002707

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923002707

Similar Items